Erratum: Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea (Otol Neurotol (2015) 36 (953–960) DOI: 10.1097/MAO.0000000000000786);Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea

Otology and Neurotology

Volumn 36, Issue 6, 2015, Pages 953-960

  Kang, Woo Seok ^a,b   Sun, Shuting ^c   Nguyen, Kim ^c   Kashemirov, Boris ^c   McKenna, Charles E ^c   Hacking, S Adam ^b   Quesnel, Alicia M ^a,b   Sewell, William F ^a   McKenna, Michael J ^a,b   Jung, David H ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Fluorescence imaging; Inner ear drug delivery; Otosclerosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL; DRUG EFFECTS; GUINEA PIG; INNER EAR; OTOSCLEROSIS; PATHOLOGY;

ANIMALS; DIPHOSPHONATES; EAR, INNER; GUINEA PIGS; IMIDAZOLES; OTOSCLEROSIS;

EID: 84933515188     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0000000000001063     Document Type: Erratum

References (43)

1. Chole RA, McKenna M. Pathophysiology of otosclerosis. Otol Neurotol 2001;22:249-57.
2. Doherty JK, Linthicum FH. Spiral ligament and stria vascularis changes in cochlear otosclerosis: effect on hearing level. Otol Neurotol 2004;25:457-64.
3. Ealy M, Smith RJ. Otosclerosis. Adv Otorhinolaryngol 2011;70:122-9.
4. Quesnel AM, Seton M, Merchant SN, et al. Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis. Otol Neurotol 2012;33:1308-14.
5. Balle V, Linthicum FH. Histologically proven cochlear otosclerosis with pure sensorineural hearing loss. Ann Otol Rhinol Laryngol 1984;93:105-11.
6. Semaan MT, Gehani NC, Tummala N, et al. Cochlear implantation outcomes in patients with far advanced otosclerosis. Am J Otolaryngol 2012;33:608-14.
7. Ramsden R, Rotteveel L, Proops D, et al. Cochlear implantation in otosclerotic deafness. Adv Otorhinolaryngol 2007;65:328-34.
8. Marshall AH, Fanning N, Symons S, et al. Cochlear implantation in cochlear otosclerosis. Laryngoscope 2005;115:1728-33.
9. Rama-Lopez J, Cervera-Paz FJ, Manrique M. Cochlear implantation of patients with far-advanced otosclerosis. Otol Neurotol 2006;27:153-8.
10. Clayton AE, Mikulec AA, Mikulec KH, et al. Association between osteoporosis and otosclerosis in women. J Laryngol Otol 2004;118:617-21.
11. McKenna MJ, Nguyen-Huynh AT, Kristiansen AG. Association of otosclerosis with Sp1 binding site polymorphism in COL1A1 gene: evidence for a shared genetic etiology with osteoporosis. Otol Neurotol 2004;25:447-50.
12. Santos F, McCall AA, Chien W, et al. Otopathology in Osteogenesis Imperfecta. Otol Neurotol 2012;33:1562-6.
13. Khetarpal U, Schuknecht HF. In search of pathologic correlates for hearing loss and vertigo in Paget's disease. A clinical and histopathologic study of 26 temporal bones. Ann Otol Rhinol Laryngol Suppl 1990;145:1-16.
14. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther 2005;5:817-32.
15. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011;49:50-5.
16. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011;49:56-65.
17. U.S. Food and Drug Administration. Full Prescribing Information for Reclast (zoledronic acid), 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021817s012lbl.pdf. Accessed May 5, 2015.
18. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8:96-110.
19. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122:S33-45.
20. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011;71:791-814.
21. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis - where do we go from here? N Engl J Med 2012;366:2048-51.
22. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(Suppl 2):S150-62.
23. Kashemirov BA, Bala JL, Chen X, et al. Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. Bioconjug Chem 2008;19:2308-10.
24. Sun S, Baazewska KM, Kashemirov BA, et al. Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 2011;186:970-1.
25. Sun S. Fluorescent imaging probes of nitrogen-containing bone active drugs: design, synthesis, and applications. Chemistry. Los Angeles: University of Southern California; 2013.
26. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-36.
27. Rasband WS, ImageJ, U. S. National Institutes of Health. Image Processing and Analysis in Java (ImageJ). Available at: http://imagej.nih.gov/ij/. Accessed May 5, 2015.
28. Kozloff KM, Volakis LI, Marini JC, et al. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 2010;25:1748-58.
29. Wen D, Qing L, Harrison G, et al. Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis 2011;17:427-32.
30. Frisch T, Sorensen MS, Overgaard S, et al. Estimation of volume referent bone turnover in the otic capsule after sequential point labeling. Ann Otol Rhinol Laryngol 2000;109:33-9.
31. Roelofs AJ, Stewart CA, Sun S, et al. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012;27:835-47.
32. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010;25:606-16.
33. Hokugo A, Sun S, Park S, et al. Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats. Bone 2013;53:59-68.
34. Vermeer JA, Jansen ID, Marthi M, et al. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than longbone marrow precursors. Bone 2013;57:242-51.
35. Bae S, Sun S, Aghaloo T, et al. Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue. Int J Mol Med 2014;34:559-63.
36. Turek J, Ebetino FH, Lundy MW, et al. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif Tissue Int 2012;90:202-10.
37. Plontke SK, Biegner T, Kammerer B, et al. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008;29:401-6.
38. Mynatt R, Hale SA, Gill RM, et al. Demonstration of a longitudinal concentration gradient along scala tympani by sequential sampling of perilymph from the cochlear apex. J Assoc Res Otolaryngol 2006;7:182-93.
39. Plontke SK, Mynatt R, Gill RM, et al. Concentration gradient along the scala tympani after local application of gentamicin to the round window membrane. Laryngoscope 2007;117:1191-8.
40. Wang X, Dellamary L, Fernandez R, et al. Principles of inner ear sustained release following intratympanic administration. Laryngoscope 2011;121:385-91.
41. Wang X, Fernandez R, Tsivkovskaia N, et al. OTO-201: Nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media. Otol Neurotol 2014;35:459-69.
42. Lajud SA, Han Z, Chi FL, et al. A regulated delivery system for inner ear drug application. J Control Release 2013;166:268-76.
43. Khoo X, Simons EJ, Chiang HH, et al. Formulations for transtympanic antibiotic delivery. Biomaterials 2013;34:1281-8.